PubRank

E Ricevuto

Author PubWeight™ 18.62‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Evaluation of widely used models for predicting BRCA1 and BRCA2 mutations. J Med Genet 2004 1.33
2 Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis. Ann Oncol 2009 1.30
3 Functional categories of TP53 mutation in colorectal cancer: results of an International Collaborative Study. Ann Oncol 2006 1.18
4 Evidence of a founder mutation of BRCA1 in a highly homogeneous population from southern Italy with breast/ovarian cancer. Hum Mutat 2001 1.01
5 Serial measurements of NT-proBNP are predictive of not-high-dose anthracycline cardiotoxicity in breast cancer patients. Br J Cancer 2011 0.96
6 Prophylactic options in patients with 5-fluorouracil-associated cardiotoxicity. Br J Cancer 2003 0.94
7 Increased tolerability of bimonthly 12-hour timed flat infusion 5-fluorouracil/irinotecan regimen in advanced colorectal cancer: A dose-finding study. Oncol Rep 2006 0.85
8 Triplet schedule of weekly 5-fluorouracil and alternating irinotecan or oxaliplatin in advanced colorectal cancer: a dose-finding and phase II study. Oncol Rep 2010 0.85
9 Reducing breast cancer incidence in familial breast cancer: overlooking the present panorama. Ann Oncol 2004 0.85
10 Cervical sarcoma botryoides treated with conservative surgery and adjuvant chemotherapy: a case report. Eur J Gynaecol Oncol 2000 0.84
11 An oncologist-based model of cancer genetic counselling for hereditary breast and ovarian cancer. Ann Oncol 2004 0.84
12 BRCA1 and BRCA2 genetic testing in Italian breast and/or ovarian cancer families: mutation spectrum and prevalence and analysis of mutation prediction models. Ann Oncol 2006 0.84
13 Short-term weekly neoadjuvant chemotherapy in the treatment of locally advanced cervical cancer. Tumori 2001 0.81
14 Ductal breast carcinoma metastatic to the vulva: a case report. Eur J Gynaecol Oncol 2001 0.80
15 p16 (INK4a, MTS-1) gene polymorphism and methylation status in human pituitary tumours. Clin Endocrinol (Oxf) 1999 0.80
16 Prognostic value of p53 molecular status in high-risk primary breast cancer. Ann Oncol 2003 0.79
17 A phase II study of dose-dense epirubicin plus cyclophosphamide followed by docetaxel plus capecitabine and pegfilgrastim support as preoperative therapy for patients with stage II, IIIA breast cancer. Ann Oncol 2007 0.78
18 Timed flat infusion of 5-fluorouracil increases the tolerability of 5-fluorouracil/docetaxel regimen in metastatic breast cancer: a dose-finding study. Br J Cancer 2004 0.77
19 [The adjuvant therapy of colonic carcinoma in old age]. Minerva Med 2000 0.76
20 Hypersensitivity reaction to carboplatin: successful resolution by replacement with cisplatin. Eur J Gynaecol Oncol 2002 0.76
21 Comment on 'Cancer genetic counselling' by P. Mandich et al. (Ann Oncol 2005; 16: 171). Ann Oncol 2005 0.75
22 [Intraperitoneal chemotherapy]. Clin Ter 1994 0.75
23 5-Fluorouracil (FU) with folinic acid (FA) and mitomycin C (MMC) in the adjuvant treatment of colorectal carcinoma. Part I. Evaluation of toxicity. Med Oncol Tumor Pharmacother 1991 0.75
24 Association of epirubicin, etoposide and cisplatin in gastric cancer. A phase II study. Oncology 1991 0.75
25 [Medical emergencies in oncology: hypercalcemia. II. Diagnosis and therapy]. Clin Ter 1990 0.75
26 Advanced non-small-cell lung cancer (NSCLC) treated with folinic acid (F), fluorouracil (FU), vincristine (O), and mitomycin-C (Mi), (F-FOMi). Am J Clin Oncol 1992 0.75
27 High-dose folinic acid (HDFA) combined with 5-fluorouracil (5-FU) in first line chemotherapy of advanced large bowel cancer. Eur J Cancer Clin Oncol 1987 0.75
28 [Weekly administration of paclitaxel: peculiarity and biological premises]. Tumori 2001 0.75
29 [Oxaliplatin: preclinical in vitro studies]. Tumori 2002 0.75
30 Sorafenib as a feasible therapeutic option in haemophiliacs with hepatocellular carcinoma. Haemophilia 2009 0.75
31 Role of immunoscintigraphy in clinical assessment of gastrointestinal tumors. Tumori 1990 0.75
32 [Mechanism of action and pharmacology of new organometallic compounds active in the treatment of colorectal neoplasms]. Tumori 2000 0.75
33 Advanced colon cancer: staging and prognosis by CEA test. Oncology 1990 0.75
34 Novel P53 mutations detected by FAMA in colorectal cancers. Ann Oncol 2006 0.75